Figure S1-S5 from Targeting Glutamine Metabolism with a Novel Na⁺/K⁺-ATPase Inhibitor RX108 in Hepatocellular Carcinoma

Supplemental Figures S1-S5</p

Supplementary Figure 4 from Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer

Supplementary Figure 4 shows that the combination of trametinib and vincristine is well tolerated in mice.</p

Supplementary Figure 6 from Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer

Supplementary Figure 6 shows that vinorelbine is also synergistic with trametinib in KRAS-mutant CRC 3D spheroids</p

Supplementary Figure 5 from Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer

Supplementary Figure 5 shows that trametinib increases the intracellular accumulation of daunorubicin in KRAS-mutant CRC cells.</p

Supplementary File 2 from Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer

HTS data using 3D CRC spheroids showing growth curves and heat maps to demonstrate efficacy of different compounds when combined with trametinib.</p

Supplementary Tables S1-S2 from Lipidomic Profiles of Plasma Exosomes Identify Candidate Biomarkers for Early Detection of Hepatocellular Carcinoma in Patients with Cirrhosis

Supplementary Table S1. Demographic and clinical parameters in 72 participants with cirrhosis (31 with HCC and 41 without HCC). Supplementary Table S2. Relative abundance (%) of the lipid classes detected in non-HCC exosomes, HCC exosomes, non-HCC plasma and HCC plasma.</p

Supplementary Figure 3 from Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer

Supplementary Figure 3 shows that the combination of trametinib and vincristine inhibits tumor growth and reduces tumor weight in PDX C1138</p

Supplementary Figure 2 from Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer

Supplementary Figure 2 shows that the combination of trametinib and vincristine reduces weight of CRC PDXs.</p

Supplementary Figure 1 from Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer

Supplementary Figure 1 shows that the combination of trametinib and vincristine is synergistic in multiple KRAS-mutant CRC cell lines and enhances apoptotic cell death.</p

Supplementary File 1 from Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer

HTS data showing efficacy of different compounds as single agents.</p